MEDIHONEY®
Antibacterial Dressing

85%* ACTIVE ANTIBACTERIAL MANUKA HONEY

MediHoney® Antibacterial Tulle application guide

MediHoney® Antibacterial Tulle dressing consists of Medical Grade Manuka Honey combined with a 3-ply non-adherent contact dressing.

PREPARE
Assess wound and cleanse according to local protocol.

APPLY
Cut fold or mold MediHoney Tulle dressing to fit within wound margins. Protect peri-wound edges with a barrier product.

COVER
Use a suitable absorbent dressing.

REMOVE
At dressing change, remove any pieces of Tulle still visible in wound bed.

MEDIHONEY® TULLE



MediHoney® Tulle dressing can be opened and used to its full extent or used as a tri-fold dressing.

Dressing frequency will depend on condition of patient and exudate levels.

At dressing change, cleanse according to local protocol and reapply dressing according to care plan.

Indications
- Leg ulcers (venous, arterial and mixed aetiology ulcers)
- Diabetic foot ulcers
- Pressure ulcers
- Infected and malodorous wounds
- Necrotic and sloughy wounds
- Donor and recipient graft sites
- 1st-and 2nd-degree burns
- Surgical wounds .

Contraindications
- Third-degree burns
- Patients with a known sensitivity to honey

i
- MediHoney has been safely used on patients of all ages
- Safe to use with diabetic patients[1-2]
- MediHoney has a low pH level of 3.5-4.5[8]
- Lowering the pH level has been associated with wound healing[3]
- Delivers Broad-spectrum antibacterial activity[4-7]

Product	Code	NHS	PIP
Tulle 5x5 cm	797	EKB093	400-9346
Tulle 10x10 cm	796	EJE067	346-3346

1. **White, R.,** MIMS Dermatology. 2006; 2(1): 40-42.
2. **Cadogan J.** The Diabetic Foot Journal; 2008; (1);43-45.
3. **Arthur Tarricone et al.** J Am Podiatr Med Assoc 1 November 2020; 110 (6): Article_13. doi: https://doi.org/10.7547/19-056
4. **Molan, Bee World.** 1992; 73, 5–28.
5. **Cooper et al.** 2002; J Burn Care Rehabil 23, 366–370
6. **Blair S.E. et al. Eur J** Clin Microbiol Infect Dis. 2009; 28, 1199–1208
7. **Maddocks et al.**, Microbiology, 2012.
8. **Boyar V. et al,** Journal of Perinatology, 2014, 34, 161–163; doi:10.1038/jp.2013.158.

Availability of these products might vary from a given country or region to another, as a result of specific local regulatory approval or clearance requirements for sale in such country or region.
▪ Non contractual document. The manufacturer reserves the right, without prior notice, to modify the products in order to improve their quality.
▪ Consult product labels and inserts for any indication, contraindications, hazards, warnings, precautions, and instructions for use.
Additional information for EMEA Customers only: The product mentioned in this document is a CE class IIb device. Contact Integra should you need any additional information on devices classification. All the medical devices mentioned on this document are CE marked, unless specifically identified as "NOT CE MARKED".

For more information or to place an order, please contact:

International +33 (0)4 37 47 59 50 ▪ +33 (0)4 37 47 59 25 fax
Benelux +32 (0)2 257 4130 ▪ +32 (0)2 253 2466 fax
France +33 (0)4 37 47 59 10 ▪ +33 (0)4 37 47 59 29 fax
Switzerland +41 (0)22 721 23 00 ▪ +41 (0)22 721 23 99 fax
United Kingdom +44 (0)1 264 345 781 ▪ +44 (0)1 264 363 782 fax
integralife.eu

CE 1639
Derma Sciences, Inc.
104 Shorting Road
Toronto, Ontario M1S 3S4 ▪ Canada

EC REP
Integra LifeSciences Services (France)
Immeuble Séquoïa 2 ▪ 97 Allée Alexandre Borodine
Parc Technologique de la Porte des Alpes
69800 Saint Priest ▪ France

INTEGRA® LIMIT UNCERTAINTY

*by weight